Semaglutide sampling was at regular time intervals ranging between 0 and 840 h after the last dose of 1.0 mg of semaglutide
AUD, in short, kills people
The reduction in cardiovascular events observed in the CVOTs is related not only to the antidiabetic properties of GLP-1 RAs but probably also to a reduction in meta-inflammation, defined as a low-grade chronic inflammatory status
Once matched, the authors look at a couple of outcomes, and the results are pretty dramatic
Assistance might be required for correct administration, especially if self-administering
Serious risks: While rare, both drugs can cause serious side effects like pancreatitis, gallbladder problems, changes in vision, and kidney issues